Abstract 3400: TY-2136b, a next generation ROS1/TRK/ALK inhibitor, potently inhibits kinase and cell proliferation activities of tumor cells bearing drug-dependent acquired mutations
Niu, Chengshan, Liang, Apeng, Dou, Yuge, Ji, Kaige, Li, Meihua, Zhao, Yanchao, Zhang, Yan, Guo, Zhongwei, Gong, Aishen, Jiang, Mingyu, Chen, Shaoqing, Chen, Xiugui, Li, Jun, Wu, Yusheng
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 3419: TY-1091, a highly selective and potent second-generation RET inhibitor, demonstrates superior antitumor activity in multiple RET-mutant models
Niu, Chengshan, Zheng, Maolin, Wang, Huan, Ji, Kaige, Li, Meihua, Wang, Guohui, Ni, Rongzhen, Liang, Apeng, Gong, Aishen, Zhang, Yazhen, Su, Hui, Jiang, Mingyu, Chen, Shaoqing, Chen, Xiugui, Li, Jun, Wu, Yusheng
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 4488: TY-4028: a novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon 20 insertion mutations
Li, Jun, Niu, Chengshan, Guo, Zhongwei, Wang, Huan, Zheng, Bailu, Dou, Yuge, Liang, Apeng, Ji, Kaige, Dong, Shengli, Li, Meihua, Zhao, Yanchao, Zhang, Yazhen, Gong, Aishen, Liu, Hao, Hu, Xinmiao, Su, Hui, Jiang, Mingyu, Chen, Shaoqing, Chen, Xiugui, Wu, Yusheng
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo
Liang, Apeng, Dong, Shengli, Liu, Guangbin, Guo, Zhengfei, Li, Meihua, Han, Shuaibo, Cao, Yundi, Tu, Yian, Zhou, Chao, Yu, Yu, Xiao, Linglin, Huang, Wei, Yang, Xinlong, Fang, Lian, Li, Haoyun, Niu, Chengshan, Jiang, Mingyu, Xing, Feng, Chen, Shaoqing, Li, Jun, Wu, Yusheng
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 5979: TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition
Li, Meihua, Niu, Chengshan, Chen, Mingtao, Ji, Kaige, Xu, Hui, Dong, Shengli, Zhang, Yan, Meng, Qinguo, Dou, Yuge, Wang, Yijun, Wu, Rui, Tu, Yian, Zhou, Chao, Liang, Apeng, Wang, Huan, Ni, Rongzhen, Gong, Aishen, Su, Hui, Jiang, Mingyu, Xing, Feng, Chen, Shaoqing, Chen, Xiugui, Li, Jun, Wu, Yusheng
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 5981: TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development
Dong, Shengli, Liang, Apeng, Zhu, Jian, Wang, Huan, Li, Meihua, Wang, Kai, Ni, Rongzhen, Li, Haoyun, Cao, Yundi, Xiao, Linglin, Li, Hongqiang, Tu, Yian, Zhou, Chao, Gong, Aishen, Xu, Shuyi, Su, Hui, Niu, Chengshan, Jiang, Mingyu, Xing, Feng, Chen, Xiugui, Chen, Shaoqing, Li, Jun, Wu, Yusheng
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article